Skip to main content

Mª Jesus Melia Grimal

Institutions of which they are part

Research technician
Neuromuscular and Mitochondrial Pathology
Vall Hebron Institut de Recerca

Mª Jesus Melia Grimal

Institutions of which they are part

Research technician
Neuromuscular and Mitochondrial Pathology
Vall Hebron Institut de Recerca

Projects

Models d'estudi de malalties degudes a manteniment defectuós del DNA mitocondrial

IP: Ramon Martí Seves
Collaborators: Mª Jesus Melia Grimal, Pau Mollá Zaragozá, Javier Francisco Ramón Pasías, Juan Luis Restrepo Vera
Funding agency: Instituto de Salud Carlos III
Funding: 208750
Reference: PI24/00838
Duration: 01/01/2025 - 31/12/2027

Estudi de malalties neuromusculars i mitocondrials

IP: Ramon Martí Seves
Collaborators: Estudi de malalties neuromusculars i mitocondrials, Elena García Arumí, Yolanda Cámara Navarro, Mª Jesus Melia Grimal, Tomàs Pinós Figueras, Javier Francisco Ramón Pasías, Andrea Férriz Gordillo, Estudi de malalties neuromusculars i mitocondrials
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 0.01
Reference: 2021 SGR 00894
Duration: 01/01/2022 - 30/06/2025

Eficacia preclínica del uso de desoxiribonucleósidos como tratamiento para los síndromes de depleción/deleciones multiples del DNA mitocondrial (MDDS). Ampliación a causas genéticas no exploradas.

IP: Ramon Martí Seves
Collaborators: Eficacia preclínica del uso de desoxiribonucleósidos como tratamiento para los síndromes de depleción/deleciones multiples del D, Mª Jesus Melia Grimal, Javier Francisco Ramón Pasías
Funding agency: Instituto de Salud Carlos III
Funding: 153670
Reference: PI21/00554
Duration: 01/01/2022 - 31/12/2025

Validación funcional de variantes en el genoma mitocondrial y nuclear en pacientes con patologia mitocondrial

IP: Elena García Arumí
Collaborators: Mª Jesus Melia Grimal, Clara Carnicer Cáceres, Paula Fernández Álvarez
Funding agency: Instituto de Salud Carlos III
Funding: 102850
Reference: PI19/01772
Duration: 01/01/2020 - 31/12/2023

Related news

The clinical trial, which also involved Vall d’Hebron, shows that the new therapy improves survival by 86% in patients with thymidine kinase 2 deficiency (TK2d).

The meeting was an opportunity to get to know projects from both institutions and to promote interaction between professionals.

The newly developed analytical workflow could in the future be introduced as a comprehensive diagnostic test for patients with mitochondrial diseases.

Related professionals

Juliana Esperalba Esquerra

Juliana Esperalba Esquerra

Research technician
Microbiology
Read more
Jaume Alijotas Reig

Jaume Alijotas Reig

Head of group
Systemic Diseases
Read more
Guillem Pons Barcons

Guillem Pons Barcons

Postdoctoral researcher
Childhood Cancer and Blood Disorders
Read more
Sergio Cabello

Sergio Cabello

Research technician
Clinical Neuroimmunology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.